Literature DB >> 9259530

Effect of an additional atropine injection during dobutamine infusion for myocardial SPET.

B Caner1, A Karanfil, U Uysal, L Tokgozoglu, S Aksoyek, O Ugur, I Ciftci, E Atalar, S Kes, C Bekdik.   

Abstract

The aim of this study was to examine the value of an additional atropine injection in patients who do not achieve an adequate heart rate during dobutamine infusion for myocardial perfusion SPET (single photon emission tomography). Patients undergoing dobutamine myocardial SPET who failed to achieve > or = 85% of their age-predicted maximal heart rate at the end of dobutamine infusion (D protocol) had a second dobutamine myocardial SPET study on a separate day with the addition of an atropine injection during the dobutamine infusion (D + A protocol). Twenty-nine patients were studied. 201Tl was used in 27 patients and 99Tc(m)-MIBI in two patients. All patients underwent coronary angiography and significant coronary artery disease was found in 19 of 29 patients. The mean heart rate obtained at the peak of dobutamine infusion in the D + A protocol was significantly higher than that in the D protocol (153.8 +/- 13.8 vs 117.5 +/- 15.3 beats min[-1]). The D + A protocol resulted in a higher diagnostic sensitivity for the detection of stenosed coronaries compared with the D protocol (87 vs 80%, P > 0.05) without changing the specificity (89% for both protocols). On the other hand, the frequency of side-effects and ECG changes during the D + A protocol was higher than that with the D protocol (32 vs 47). In conclusion, the addition of an atropine injection during dobutamine infusion resulted in a higher diagnostic sensitivity for identifying stenosed coronaries compared to dobutamine alone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259530     DOI: 10.1097/00006231-199706000-00012

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

1.  Safety and feasibility of atropine added to submaximal exercise stress testing with Tl-201 SPECT for the diagnosis of myocardial ischemia.

Authors:  Sanjay K Prasad; Dudley J Pennell
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

2.  Safety and feasibility of atropine added to submaximal exercise stress testing with Tl-201 SPECT for the diagnosis of myocardial ischemia.

Authors:  Juan Cosín-Sales; Alicia M Maceira; María J García-Velloso; Alfonso Macías; Marta Gimenez; Ignacio García-Bolao; Isabel Coma-Canella
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

Review 3.  Diagnosis of coronary artery disease by radionuclide myocardial perfusion imaging.

Authors:  C Y Loong; C Anagnostopoulos
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

4.  Atropine for exercise testing after acute myocardial infarction.

Authors:  Eliana Reyes
Journal:  Int J Cardiovasc Imaging       Date:  2005-08       Impact factor: 2.357

5.  Use of atropine in patients with recent myocardial infarction during exercise myocardial perfusion study. Use of atropine during exercise myocardial perfusion SPECT.

Authors:  S Barai; C D Patel; A Malhotra; G P Bandopadhayaya; S Gambhir; R Kumar; H Dhanapathi
Journal:  Int J Cardiovasc Imaging       Date:  2005-08       Impact factor: 2.357

6.  Safety and feasibility of atropine added in patients with sub-maximal heart rate during exercise myocardial perfusion SPECT.

Authors:  Filippo Maria Sarullo; Corrado Ventimiglia; Andrea Taormina; Vincenzo Azzarello; Filippo Felice; Annamaria Martino; Salvatore Paterna; Pietro Di Pasquale
Journal:  Int J Cardiovasc Imaging       Date:  2006-11-16       Impact factor: 2.316

Review 7.  Myocardial perfusion scintigraphy: the evidence.

Authors:  S R Underwood; C Anagnostopoulos; M Cerqueira; P J Ell; E J Flint; M Harbinson; A D Kelion; A Al-Mohammad; E M Prvulovich; L J Shaw; A C Tweddel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.